Former Amylin Pharmaceuticals Chief Executive Officer brings more than 40 years of experience building and leading life sciences companies
RENO, Nevada, November 19, 2026 (GLOBE NEWSWIRE)-- ConexeuSciences Inc. (Nasdaq: CNXU) ("Conexeu" or the"Company"), a preclinical-stage regenerative tissue platform company, today announced the appointment of Daniel M. Bradbury as Chairman of the Board of Directors, effective December 1, 2026. Mr. Bradbury succeeds Jeff Sharpe, who has stepped down as Chairman and director of the Company to specifically make way for Mr. Bradbury.
Mr. Bradbury brings more than 40 years of experience creating andcarrying out strategies that transform businesses, bring novel medicines to market, and build shareholder value. He served as President and Chief Executive Officer of Amylin Pharmaceuticals, Inc. from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012, in a transaction valued at approximately $7 billion. During his 18-year tenure at Amylin, the company launched three first-in-class medicines, including the first once-weekly therapy to treat diabetes, and was listed on the Nasdaq 100. Before joining Amylin, he spent ten years in marketing and sales roles at SmithKline BeechamPharmaceuticals.
Mr. Bradbury is Chairman and Co-Founder of Equillium, Inc. (Nasdaq: EQ),where he served as Chief Executive Officer until January 2020 and as Executive Chairman until October 2025, and led the company through its initial public offering. He is Chairman of the Board of Castle Biosciences, Inc. (Nasdaq: CSTL) and an independent director of Vivani Medical, Inc. (Nasdaq: VANI) and Biocon Limited (NSE: BIOCON). He previously served on the boards of Illumina, Inc.,Geron Corporation, Corcept Therapeutics, Inc., BioMed Realty Trust, Inc. andIntercept Pharmaceuticals, Inc., and has chaired the boards of a number of private life sciences companies. He is the Managing Member of BioBrit, LLC, a Life Sciences Consulting and Investment Firm based in La Jolla, CA.
In 2023, the Corporate Directors Forum named Mr. Bradbury Director of the Year for Lifetime Achievement in Corporate Governance. He holds a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from the University of West London and completed the Director Certification Program at the University of California, Los Angeles.
The Board thanks Mr. Sharpe for his leadership as Chairman andpast CEO, including guiding the Company through its listing on Nasdaq in May 2026.
"On behalf of the Board and the entire Conexeu team, I want to thank Jeff for his leadership and commitment. He guided Conexeu through its Nasdaq listing and helped build the foundation we stand on today," said Miles Harrison, President and Chief Executive Officer of Conexeu. "We are delighted to welcome Dan as Chairman. He has led a company from development through regulatory approval, commercial launch and a major acquisition, and has chaired the boards of public and private life sciences companies for more than a decade. His experience will be invaluable as we prepare for our planned510(k) submission and the commercial steps that follow."
"Conexeu has built a regenerative tissue platform with broad potential in areas of high unmet need," said Mr. Bradbury. "I am pleased to join the Board as Chairman at an important point in the Company's development. I look forward to working with Miles, the Board, and the management team as Conexeu moves toward its first regulatory submission and commercial entry. I also thank Jeff for his service and for the strong position in which he leaves the Board."
AboutConexeu Sciences Inc.
Architecting Bioregeneration™. Conexeu Sciences is a preclinical-stage medical device company. Our patent-protected collagen-based scaffold platform, CXU™, is built on a single structural principle: one core technology platform being exploredacross multiple device formats and potential tissue-restoration applicationsand designed to scale across multiple addressable markets.
Conexeu is targeting large, multi-billion-dollar end markets, including wound care, periodontal applications, and facial and body soft-tissue applications, including the tissue changes that can follow GLP-1 weight loss, with further expansion opportunities in 3D printing and biofabrication workflows and the veterinary market. The Company is advancing a predicate-based U.S. regulatory strategy with an anticipated 510(k) submission in the first calendar quarter of 2027 for its initial indication, subject to regulatory review. Conexeu is led by an experienced leadership team with deep expertise in biomaterials, wound care and medical device commercialization and development.
For more information, visit www.conexeu.com
Trademarks. CXU™, is a trademarks of ConexeuSciences Inc.
Forward-LookingStatements
Exceptfor the statements of historical fact contained herein, the informationpresented in this news release constitutes “forward-looking statements” as suchterm is used in applicable United States securities laws. These statementsrelate to analysis and other information that are based on forecasts or futureresults, estimates of amounts not yet determinable, and assumptions ofmanagement, including, but not limited to, statements regarding regulatorypathway, submission timing, category development and platform expansion. Anyother statements that express or involve discussions with respect topredictions, expectations, beliefs, plans, projections, objectives, assumptionsor future events or performance (often, but not always, using words or phrasessuch as “expects”, or “does not expect”, “is expected”, “anticipates” or “doesnot anticipate”, “plans”, “estimates” or “intends”, or stating that certainactions, events or results “may”, “could”, “would”, “might” or “will” be taken,occur or be achieved) are not statements of historical fact and should beviewed as “forward-looking statements”. We have based these forward-lookingstatements on our current expectations about future events or performance.While we believe these expectations are reasonable, such forward-lookingstatements are inherently subject to risks and uncertainties, many of which arebeyond our control. Our actual future results may differ materially from thosediscussed or implied in our forward-looking statements for various reasons. Factorsthat could contribute to such differences include, but are not limited to:international, national and local general economic and market conditions;demographic changes; the early-stage, preclinical nature of the Company'sdevice candidates, including B.R.E.A.S.T.™ and Ten Minute Tissue™, and theinherent uncertainty of preclinical and clinical development, including thepossibility that preclinical results may not be predictive of clinicaloutcomes; preclinical study objectives described as met may not result inclinical benefit, regulatory clearance, or commercial success; third partymarket estimates disclosed herein, including GLP-1, aesthetics and injectablemarket figures may prove inaccurate or may not reflect the Company’saddressable market; the investigational status of CXU™, which is not cleared orapproved for marketing in any jurisdiction, and that no assurance can be giventhat any such clearance or approval will be obtained; risks associated with theCompany's planned 510(k) submission, including the possibility that thesubmission may not be completed within the anticipated first-quarter 2027timeframe or at all; the risk that the FDA may not accept the 510(k) submissionas filed, may request additional information, data, or testing, or maydetermine that the device is not substantially equivalent to the identifiedpredicate device; the risk that marketing clearance for the CXU™ wound-caredevice may not be obtained, may be delayed, or may be subject to conditions orlimitations that affect the Company's commercial plans; changes in FDAregulatory policy, guidance, or review standards applicable to 510(k)submissions or the Company's identified predicate devices; the ability of theCompany to sustain, manage or forecast its growth; the ability of the Companyto develop and commercialize its products; the ability of the Company to raisecapital to complete its plans and fund its operations; the risk that theCompany's human collagen program may not achieve the yield, consistency,purity, sterility or scale required for use in a medical device; the risk thatresults from internal testing of an initial batch may not be reproduced insubsequent batches or in independent testing; the risk that any CXU™ productincorporating human collagen will require separate regulatory review and maynot be cleared or approved; risks related to the sourcing, qualification andregulatory requirements applicable to human-derived biological materials; thecontinued availability of key leadership personnel; adverse publicity;competition and changes in the advanced wound care market, medical aestheticsmarket and tissue engineering and reconstruction; fluctuations and difficultyin forecasting operating results; business disruptions, such as technologicalfailures and/or cybersecurity breaches; and the other risks described in theCompany's filings with the SEC, including under “Risk Factors” in its mostrecent Annual Report on Form 10-K and subsequent Quarterly Reports on Form10-Q. There can be no assurance that such statements will prove to be accurateas actual results, and future events could differ materially from thoseanticipated in such statements. Accordingly, readers should not place unduereliance on forward-looking statements contained in this news release and inany document referred to in this news release. The forward-looking statementsincluded in this release are made only as of the date hereof. For forward-lookingstatements in this news release, the Company claims the protection of the safeharbor for forward-looking statements contained in the Private SecuritiesLitigation Reform Act of 1995. The Company assumes no obligation to update orsupplement any forward-looking statements whether as a result of newinformation, future events or otherwise. This news release shall not constitutean offer to sell or the solicitation of any offer to buy our securities.
###

